The cause of platelet agglutination in thrombotic thrombocytopenic purpura has been an enigma. Current evidence indicates that the interaction of platelets with a platelet-aggregating factor or unusually large multimers of factor Vlllrvon Willebrand factor, or both, may cause the abnormal platelet agglutination. Recent success in the treatment of thrombotic thrombocytopenic purpura with intravenous infusion of immunoglobulin suggests that the abnormal platelet agglutination in thrombotic thrombocytopenic purpura may reflect a deficiency of immunoglobulins that nor mally inhibit platelet-aggregating factors or large multimers of factor VIII:von Willebrand factor.
In 1924, Moschcowitz initially described a fulmi nant febrile illness in a 16-year-old girl charac terized by the diffuse deposition of hyaline thrombi in terminal arterioles. 1, 2 In this original description of thrombotic thrombocytopenic purpura (TTP), Moschcowitz reported pallor, petechiae, fever, and slight paralysis. Labora tory studies revealed anemia and proteinuria. Nucleated erythrocytes were present in the peripheral blood smear; no schistocytes were described. No platelet count was obtained. At autopsy, hyaline thrombi were seen in "every section of heart muscle"; occasional thrombi were present in the spleen, liver, and kidneys. Mosch cowitz stated, incorrectly, that the hyaline thrombi resulted from the agglutination of eryth- rocytes. He concluded that a toxin with pro nounced hemolytic and agglutinating properties was the cause of the diffuse thrombotic process. TTP is a very rare disease. Petitt 3 calculated an incidence of about one case per million popu lation in Olmsted and Fillmore counties in his review of the Mayo Clinic experience for a 30-year period (1950 through 1979) . The peak incidence is in the fourth decade of life, and 60% of cases occur in women. 4 
MANIFESTATIONS
The characteristic clinical pentad of TTP con sists of thrombocytopenic purpura, microangiopathic hemolytic anemia, varying neurologic symptoms or signs, renal disease, and fever.
are the renal abnormalities. The cause of the moderate increases in body temperature is unknown. Anemia is frequently severe, the hemoglobin concentration being less than 5.5 g/dl in 30% of the patients.
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Consistent with this nonimmune intravascular hemolytic process, the peripheral blood smear demonstrates schistocytes without spherocytes. The indirect bilirubin, lactate dehydrogenase, reticulocyte count, and plasma hemoglobin val ues are increased, and hemosiderin is present in the urine. Additionally, haptoglobin is decreased or absent, and the direct Coombs test is nega tive. Thrombocytopenia is pronounced; platelet counts seldom exceed 20,000/mm 3 . Marrow megakaryocytes are normal or increased. Al though fibrinogen may be consumed inadver tently during the process of diffuse platelet agglutination, mild disseminated intravascular coagulation is uncommon. Other clinical mani festations may include cardiac dysfunction, hepatosplenomegaly, and pancreatitis.
DIAGNOSIS
The diagnosis of TTP is suggested by the afore mentioned clinical pentad; no specific diagnostic test exists. The presence of hyaline thrombi in biopsy specimens of skin, subcutaneous tissue, muscle, bone marrow, gingiva, or lymph nodes lends support to the diagnosis. These microvascular occlusions are evidence of the diffuse plate let agglutination that characterizes TTP. The differential diagnosis of TTP includes the hemo lytic uremie syndrome, disseminated intravas cular coagulation, autoimmune hemolytic ane mia, immune thrombocytopenic purpura, Evans' syndrome, immune-mediated microangiopathy (such as systemic lupus erythematosus), subacute bacterial endocarditis, nonbacterial thrombotic endocarditis, meningococcemia, dissemi nated carcinomatosis, malignant hypertension, eclampsia, and the HELLP (/lemolysis with elevated Ziver enzymes and Zow platelet count) preeclamptic syndrome. 6 The hemolytic-uremic syndrome may occur in adults; although similar to TTP clinically, the platelet agglutination is primarily limited to the kidney. Although investigators agree that the intra vascular hyaline thrombi are composed primar ily of platelet aggregates, the sequence of events leading to this platelet agglutination remains controversial. Whether endothelial vascular damage initiates or results from the platelet agglutination is unclear. In support of a primary vasculopathy, subintimai "prethrombotic" hya line deposits containing immunoglobulin have been observed in areas devoid of intraluminal thrombi. An immunoglobulin cytotoxic for cul tured endothelial cells was isolated from the serum of three patients with TTP. 9 An alterna tive suggestion is that the vascular endothelial cell proliferation noted in TTP is simply reendothelialization caused by previous local platelet agglutination.
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Endothelial damage may be responsible for the localized absence of fibrinolysis that distin guishes TTP from other disseminated intravas cular coagulopathies; however, because plate lets contain large quantities of inhibitors of both plasminogen activator and plasmin, the plate let-rich thrombi that characterize TTP are resis tant to fibrinolysis.
platelets. Prostacyclin is a naturally occurring inhibitor of platelet aggregation and is synthe sized by the vascular endothelium. A deficiency of this mediator has been demonstrated by sev eral investigators, and infusion of prostacyclin has reversed platelet aggregation in vivo. 10 Kitch ens 11 described "exhausted" platelets in a young woman with TTP, who had prolongation of the bleeding time and bruising just before thrombocytopenic relapse.
The most cogent explanations reflect increas ing understanding of the interactions of the platelet-aggregating activity described by Lian and associates, 12 · 14 unusually large multimers of VIILvWF, and the lack of inhibitors of these substances.
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In 1977, Bukowski and colleagues 17 demon strated that most patients with TTP respond to plasma exchange. This finding suggested that the disease could be controlled by removal of a "toxic" substance that caused platelets to aggre gate. Previous and subsequent successful treat ment with plasma infusion alone led Lian and co-workers 14 and Aster 13 to suggest that TTP resulted from a deficiency of a normal plasma component. Purification of the protein (or pro teins) of the platelet-aggregating activity is currently in progress. 18 Murphy and asso ciates 19 recently suggested that a calciumdependent cysteine protease is responsible for the platelet-aggregating activity in TTP.
Plasma from patients with TTP will induce agglutination of both washed platelets from normal donors and platelets from patients with TTP in remission. The platelet-aggregating activity of plasma from patients with TTP di minishes as a function of time during incubation with normal plasma at 37°C. 
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Infusion of immunoglobulin has been shown to halt platelet agglutination both in vitro and in vivo. In acute TTP, perhaps an initial insult (such as pregnancy, drugs, infection, or tissue necrosis) triggers production of a plateletagglutinating factor that causes, or is associated with, a subtle defect or deficiency in the humoral immune response during the disease state only. 12 Lian and Savaraj 20 demonstrated that plate let agglutination induced in vitro did not neces sitate the production of thromboxane A 2 , pro mote release of platelet granule contents, or alter metabolism of platelets or flux of calcium or magnesium ions.
vWF is synthesized by megakaryocytes and vascular endothelium. It is present in platelet ot granules and is stored in the Weibel-Palade bodies. In plasma, it circulates as multimers of 4 to 60 subunits (molecular weights 1 to 21 x 10 6 ) in a flexible filament that interacts with fibrinogen and is necessary for platelet adhesion to injured subendothelium at the high shear rates of rapid blood flow. 21 In vitro, ristocetin (a positively charged substance) induces attach ment of the largest VIILvWF multimene forms present in normal plasma to platelets and pro motes platelet agglutination. 8 In 1982, Moake and co-workers 8 observed that the platelet agglutination in patients with TTP was similar to the platelet agglutination in duced in vitro by large multimeric vWF compo nents of VIILvWF. They found unusually large VIII : vWF multimers in four patients with chronic relapsing TTP. The plasma levels of the multi mers decreased during clinical relapses, a result that suggests binding to (and subsequent agglu tination of) platelets. During clinical remis sions, these same patients had abnormally high concentrations of these unusually large VIILvWF multimers.
Moake and associates 8 suggested that pa tients with chronic TTP lack the ability to cleave large VIILvWF multimers. They speculated that certain initiating factors (for example, preg nancy, drugs, infection, or tissue necrosis) re lease cationic polyamines (an in vivo ristocetin), which then neutralize the negatively charged platelet membrane and thus allow large mul timers of VIILvWF to be adsorbed and promote platelet agglutination. This sequence of events may result from a deficiency of or a defect in VIILvWF depolymerase, which normally de grades these large multimers. The platelet agglutination induced by large multimers is inhibited by immunoglobulin (the activity is in the Fc fragment, in contrast to the Fab location of anti-platelet-agglutinating factor activity) by its binding to the platelet membrane Fc recep tor.
12 Transfusion of a normal spectrum of factor VIII :vWF has reversed the hématologie abnor malities in one patient with TTP in whom un usually large vWF multimers had previously been demonstrated. 22 In 1984, Kelton and colleagues 15 suggested that both the platelet-aggregating activity de scribed by Lian and co-workers 14 and the unusu ally large multimers of VIILvWF described by Moake and associates 8 were involved in the platelet agglutination that characterizes TTP. They described a method for the qualitative detection of platelet-agglutinating activity and noted that this activity was augmented by the addition of large VIILvWF multimers.
The concentration of platelet-associated im munoglobulin is frequently increased in patients with TTP.
12 23 The level of platelet-associated antibody has been correlated with disease ac tivity. 24 Perhaps immunoglobulins directed against platelet-agglutinating factor and large multimers of VIILvWF are responsible for this increase. Figure 1 depicts the current theory of the potential pathogenesis of TTP. TTP is a syn drome with diverse causes and probably differ ent pathogenetic mechanisms. An excellent review of the diverse pathogenesis of TTP has recently been published by Lian. 25 In addition, extensive material on thrombotic microangiopathy organized by Kwaan 26 should be of interest to hematologists.
TREATMENT
The therapeutic effect of single agents in pa tients with TTP is difficult to determine because multiple treatment modalities are generally used concomitantly for this life-threatening disease. Treatment options include the following: corti costeroids, antiplatelet agents (such as dextran, sulfinpyrazone, aspirin, or dipyridamole), prostacyclin, infusion of plasma, plasma exchange, Vinca alkaloids, splenectomy, and infusion of immunoglobulin.
Currently, initial therapy generally includes antiplatelet agents (aspirin and dipyridamole), corticosteroids, and either plasma exchange or infusion of fresh-frozen plasma.
Although in vitro data suggest that platelet inhibitors fail to prevent platelet aggregation, 20 the survival rate of patients treated with anti platelet agents (aspirin and dipyridamole) and concurrent plasma manipulation is improved. 27 Perhaps the inhibition of platelet adhesion and of further platelet aggregation and release in vivo explains the beneficial effects of platelet inhibitors in patients with TTP. 20 The ineffec tiveness of platelet inhibitors (and the bleeding complications) noted by one group of investiga tors 28 may have been due to suppression of the platelet-inhibiting effect of prostacyclin. 29 Infusion of prostacyclin has reversed TTP in vivo but is associated with severe hypotension from its vasodilatory effects.
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One brief con trolled trial demonstrated an increase in fatal cerebral hemorrhage with use of heparin. 27 Although platelet transfusions occasionally have been given because of bleeding associated with severe thrombocytopenia, Harkness and co-workers 30 described a young female patient with TTP who had rapid deterioration of the central nervous system (with autopsy evidence of extensive deposition of platelet aggregates within the small blood vessels of the brain) immediately after the transfusion of platelets. This outcome raises the possibility t h a t platelet transfusion may fuel ongoing platelet agglutina tion. Moreover, Gordon and associates 31 ex tended this observation by noting that, in addi tion to platelet transfusion, reaccumulation of the circulating platelet pool (as a result of rever sal of the disease process) also may be associated with clinical deterioration. They suggested that antiplatelet therapy be delayed until platelet counts begin to increase steadily in response to initial treatment (plasmapheresis with freshfrozen plasma and corticosteroids). Infusion of fresh-frozen plasma has been the basis of successful treatment of TTP, perhaps by supplying the immunoglobulin inhibitors to platelet-agglutinating factor and VIILvWF. Plasma exchange may be used if infusion of fresh-frozen plasma is inadequate or compli cated by volume overload. The added efficacy of plasma exchange over infusion of fresh-frozen plasma 32 in some patients may reflect the re moval of large VIILvWF multimers or plateletaggregating activity.
Other treatment options include splenectomy, Vinca alkaloids, and infusion of immunoglob ulin. The demonstrated effectiveness of infusion of immunoglobulin in halting platelet agglutina tion in patients with TTP 12 · 13 makes such treat ment an attractive option. In one recently re ported case, TTP was treated successfully with. infusion of high doses of immunoglobulin after the failure of plasmapheresis, exchange transfu sion, splenectomy, antiplatelet agents, glucocorticoids, and vincristine. 33 
CONCLUSION
TTP has changed from a disease once univer sally fatal to an illness that, when recognized, has a remission rate exceeding 90%. Increasing success in the treatment of TTP with the use of plasma and its components is unlocking etiologic secrets. 
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